Salina Yuan

Salina Yuan

Auto-generated profile, based on publicly available information

Salina Yuan

Department of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 July 2018 in Immunity
Verified
Journal Article
Closed access
JLJinyang Li
Jinyang Li
KBKatelyn T. Byrne
Katelyn T. Byrne
FYFangxue Yan
Fangxue Yan
TYTaiji Yamazoe
Taiji Yamazoe
ZCZeyu Chen
Zeyu Chen
BSBen Z. Stanger
Ben Z. Stanger

1 June 2018 in Developmental Cell
Verified
Journal Article
Closed access
NANicole M. Aiello
Nicole M. Aiello
RMRavikanth Maddipati
Ravikanth Maddipati
RNRobert J. Norgard
Robert J. Norgard
DBDavid Balli
David Balli
JLJinyang Li
Jinyang Li
BSBen Z. Stanger
Ben Z. Stanger

1 July 2019 in Cancer Discovery
Verified
Journal Article
Open access
PDF file
SYSalina Yuan
Salina Yuan
RNRobert J. Norgard
Robert J. Norgard
BSBen Z. Stanger
Ben Z. Stanger
During cancer progression, tumor cells undergo molecular and phenotypic changes collectively referred to as cellular plasticity. Such changes result from microenvironmental cues, stochastic genetic and epigenetic alterations, and/or treatment-imposed selective pressures, thereby contributing to tumor heterogeneity and therapy resistance. Epithelial–mesenchymal plasticity is the best-known case of tumor cell plasticity, but recent work has uncovered other examples, often with functional consequences. In this review, we explore the nature and role(s) of these diverse cellular plasticity programs in premalignant progression, tumor evolution, and adaptation to therapy and consider ways in which targeting plasticity could lead to novel anticancer treatments. Significance: Changes in cell identity, or cellular plasticity, are common at different stages of tumor progression, and it has become clear that cellular plasticity can be a potent mediator of tumor progression and chemoresistance. Understanding the mechanisms underlying the various forms of cell plasticity may deliver new strategies for targeting the most lethal aspects of cancer: metastasis and resistance to therapy.

6 December 2022 in Cancer Discovery
Verified
Journal Article
Open access
PDF file
SKSamantha B. Kemp
Samantha B. Kemp
NCNoah Cheng
Noah Cheng
NMNune Markosyan
Nune Markosyan
RSRina Sor
Rina Sor
IKIl-Kyu Kim
Il-Kyu Kim
BSBen Z. Stanger
Ben Z. Stanger
Mutations in the KRAS oncogene are found in more than 90% of patients with pancreatic ductal adenocarcinoma (PDAC), with Gly-to-Asp mutations (KRASG12D) being the most common. Here, we tested the efficacy of a small-molecule KRASG12D inhibitor, MRTX1133, in implantable and autochthonous PDAC models with an intact immune system. In vitro studies validated the specificity and potency of MRTX1133. In vivo, MRTX1133 prompted deep tumor regressions in all models tested, including complete or near-complete remissions after 14 days. Concomitant with tumor cell apoptosis and proliferative arrest, drug treatment led to marked shifts in the tumor microenvironment (TME), including changes in fibroblasts, matrix, and macrophages. T cells were necessary for MRTX1133's full antitumor effect, and T-cell depletion accelerated tumor regrowth after therapy. These results validate the specificity, potency, and efficacy of MRTX1133 in immunocompetent KRASG12D-mutant PDAC models, providing a rationale for clinical testing and a platform for further investigation of combination therapies. Significance: Pharmacologic inhibition of KRASG12D in pancreatic cancer models with an intact immune system stimulates specific, potent, and durable tumor regressions. In the absence of overt toxicity, these results suggest that this and similar inhibitors should be tested as potential, high-impact novel therapies for patients with PDAC. See related commentary by Redding and Grabocka, p. 260. This article is highlighted in the In This Issue feature, p. 247

1 July 2017 in Molecular Cell
Verified
Journal Article
Closed access
SSSharanya Sivanand
Sharanya Sivanand
SRSeth Rhoades
Seth Rhoades
QJQinqin Jiang
Qinqin Jiang
JLJoyce V. Lee
Joyce V. Lee
JBJoseph Benci
Joseph Benci
KWKathryn E. Wellen
Kathryn E. Wellen

1 July 2014 in Cancer Cell
Verified
Journal Article
Closed access
LWLiling Wan
Liling Wan
XLXin Lu
Xin Lu
SYSalina Yuan
Salina Yuan
YWYong Wei
Yong Wei
FGFeng Guo
Feng Guo
YKYibin Kang
Yibin Kang